Aug 31, 2026, 23:15 UTC
Astellas Pharma Inc. announced a voluntary agreement with the U.S. government to lower Medicaid medicine prices, align future pricing with international benchmarks, and donate 25 kg of tacrolimus API to the U.S. Strategic Active Pharmaceutical Ingredients Reserve.
Aug 31, 2026, 19:14 UTC
President Donald J. Trump announced agreements with nine additional pharmaceutical manufacturers to lower drug prices for Americans in line with most-favored-nation pricing.
Aug 28, 2026, 23:59 UTC
Astellas Pharma announced it has become the first Host City Partner for the One Young World 2027 Tokyo Summit, scheduled to take place at the Tokyo International Forum from September 28 to October 1, 2027.
Source:Aug 19, 2026, 09:15 UTC
Central Carolina Community College opened the E. Eugene Moore Manufacturing and Biotech Solutions Center in Lee County, North Carolina, with a ribbon-cutting ceremony, unveiling the Kyowa Kirin Innovation Hub.
Source:Jul 13, 2026, 04:12 UTC
Astellas Pharma announced that the U.S. FDA approved an expanded indication for its anticancer drug Padcev to include muscle-invasive bladder cancer patients regardless of cisplatin eligibility.
Jul 10, 2026, 15:23 UTC
The U.S. FDA approved PADCEV plus Keytruda as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer.
Jun 26, 2026, 13:53 UTC
Lupin Ltd. received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Enzalutamide Tablets in multiple strengths.
Jun 23, 2026, 00:00 UTC
Sangamo Therapeutics filed for Chapter 11 bankruptcy and signed stalking horse asset purchase agreements with Eli Lilly and Astellas to sell its assets in a bankruptcy auction.